This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Oct 10;37(29):2587-2591.

doi: 10.1200/JCO.18.02257. Epub 2019 Jul 1.

Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?

Francisco E Vera-Badillo¹, Ian F Tannock², Christopher M Booth¹

Affiliations

PMID: 31260641
DOI: 10.1200/JCO.18.02257

Comment

Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?

Francisco E Vera-Badillo et al. J Clin Oncol. 2019.

. 2019 Oct 10;37(29):2587-2591.

doi: 10.1200/JCO.18.02257. Epub 2019 Jul 1.

Authors

Francisco E Vera-Badillo¹, Ian F Tannock², Christopher M Booth¹

Affiliations

¹ Queen's University, Kingston, Ontario, Canada.
² Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

PMID: 31260641
DOI: 10.1200/JCO.18.02257

No abstract available

PubMed Disclaimer

Comment on

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Rosenberg JE, et al. J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29. J Clin Oncol. 2019. PMID: 31356140 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.